GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

Prior Therapy

1st Line

IRB #2377 A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma

IRB #20410 New study to be available soon

IRB #20744 New study to be available soon

2nd Line

IRB# 19185 Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

IRB# 17603 Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

IRB# 20506 New study to be available soon

IRB #20357 [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB #16033 New study to be available soon

Cholangiocarcinoma

1st Line

IRB # 19095 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

Cross-Disease Trials:

IRB# TBD

EAY131 (MATCH)

2/4/2020

http://www.ohsu.edu/research/rda/so/knight.php